Product image of Leruze (Lisinopril Anhydrous) supplied by GNH India

Leruze

Active Ingredient:
Lisinopril Anhydrous
Origin:
EU

Leruze (Lisinopril Anhydrous)

Lisinopril, the active ingredient in Leruze, is an ACE inhibitor presented as an oral tablet for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with heart failure or post‑myocardial infarction.

GNH India supplies Leruze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive technical support, regulatory documentation, and timely delivery across multiple continents.

Manufacturer / TM Owner

Rafarm Sa.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lisinopril is used to manage conditions within the cardiovascular disease pathway, primarily by controlling blood pressure and reducing cardiac workload.

  • Hypertension: lowers systemic blood pressure, decreasing risk of stroke and kidney damage.
  • Heart failure: improves symptoms and reduces hospitalization by decreasing afterload.
  • Post‑myocardial infarction: lowers mortality and prevents remodeling of the heart muscle.

How It Works

  • Lisinopril selectively inhibits the angiotensin‑converting enzyme (ACE), preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This inhibition leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, collectively lowering arterial pressure and easing cardiac workload. By maintaining higher levels of bradykinin, it also contributes to endothelial nitric oxide release, further supporting vascular relaxation. The net effect is a sustained reduction in systemic vascular resistance.

Side Effects

Lisinopril may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Cough: dry, persistent cough.
  • Dizziness: especially upon standing.
  • Headache: mild to moderate intensity.
  • Fatigue: general tiredness.
  • Hyperkalemia: elevated blood potassium levels.
  • Hypotension: low blood pressure, particularly after first dose.

Serious or Rare Side Effects

  • Angioedema: swelling of face, lips, tongue, or airway.
  • Renal impairment: worsening kidney function.
  • Hepatitis: signs of liver injury.
  • Neutropenia: reduced white blood cell count.
  • Severe hypotension: marked drop in blood pressure causing fainting.

Precautions & Warnings

When prescribing Lisinopril, clinicians should observe several safety considerations to minimize risk.

  • Pregnancy: contraindicated in second and third trimesters due to fetal toxicity (Category D).
  • Renal function: assess baseline creatinine and monitor regularly.
  • Hyperkalemia risk: avoid concurrent potassium‑sparing diuretics or supplements.
  • Hypotension: start at low dose in patients prone to low blood pressure.
  • Drug interactions: review concomitant medications for ACE inhibitor interactions.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Avoid Interactions

Lisinopril can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Aliskiren: combined use in diabetes or renal impairment may increase risk of renal dysfunction.
  • Lithium: may increase lithium levels, risking toxicity.
  • NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

  • Potassium‑sparing diuretics (e.g., spironolactone): may cause hyperkalemia.
  • Angiotensin II receptor blockers: additive blood pressure lowering, monitor for hypotension.
  • Diuretics (thiazides): may enhance hypotensive effect, adjust dose as needed.

Frequently Asked Questions

Leruze contains lisinopril, an ACE inhibitor that is prescribed to treat high blood pressure (hypertension), manage chronic heart failure, and improve outcomes after a myocardial infarction. By lowering systemic vascular resistance, it helps reduce the workload on the heart and lowers the risk of cardiovascular complications.

Lisinopril blocks the angiotensin‑converting enzyme, which prevents the formation of angiotensin II, a powerful vasoconstrictor. This results in dilation of blood vessels, reduced secretion of aldosterone, and decreased sodium and water retention, collectively lowering arterial pressure and easing cardiac strain.

The dosage of Leruze is individualized. A qualified prescriber determines the appropriate strength and frequency based on the patient’s clinical condition, response to therapy, and any relevant laboratory values. Patients should follow the prescribing information provided by their healthcare professional.

Lisinopril is classified as Pregnancy Category D, indicating evidence of fetal risk and it is contraindicated in the second and third trimesters. Limited data are available for breastfeeding; because the drug is excreted in milk, caution is advised and alternative therapy is usually preferred.

To request Leruze, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Leruze belongs to the ACE inhibitor class, which differs from angiotensin‑II receptor blockers (ARBs) by directly inhibiting ACE rather than blocking the receptor. Compared with ARBs, ACE inhibitors may cause a dry cough but have a well‑established record for reducing mortality after myocardial infarction.

Leruze tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity.

Leruze is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber, especially regarding the timing of the first dose.

The most serious adverse events include angioedema (rapid swelling of the face, lips, tongue, or airway), severe hypotension especially after the first dose, acute renal failure, and significant hyperkalemia. Patients should seek immediate medical attention if they experience any of these symptoms.

Leruze is contraindicated in patients with a known history of angioedema related to ACE inhibitors, in pregnant women (especially after the first trimester), and in individuals with severe renal impairment or hyperkalemia. Caution is also advised for patients on concurrent potassium‑sparing diuretics or lithium.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lisinopril Anhydrous

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT